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Basaloid squamous cell carcinoma (BSCC) and carcinosarcoma of the esophagus are rare entities, making up fewer than 2% of esophageal malignancies. Comparative genomic hybridization (CGH) in
Basaloid squamous cell carcinoma (BSCC) and carcinosarcoma of the esophagus are considered rare histomorphologic variants of squamous cell carcinoma (SCC), constituting fewer than 2% of primary esophageal malignancies. 1, 2 Both entities usually develop in men with a mean age of about 60 years. 1, 3 BSCC exhibits a locally invasive growth pattern, a poor degree of differentiation, high proliferation activity, and a high incidence of distant metastasis. 4 In contrast, carcinosarcoma displays a bulky mass with an exophytic growth pattern in the mid to lower esophagus causing marked esophageal stenosis and rather late metastatic spread. 1, 5 We describe the chromosomal aberrations in BSCC and carcinosarcoma of the esophagus by using comparative genomic hybridization (CGH) and array CGH with emphasis on common copy number changes.
Case Reports

Case 1 (BSCC)
A 52-year-old man was admitted to University Medical Center Göttingen, Göttingen, Germany, with a 6-month history of an unexplained weight loss of 12 kg. His medical history included chronic pancreatitis, type 2 diabetes mellitus, coronary arteriosclerosis, alcohol abuse, and smoking. His family history was uneventful for malignancies. Barium swallow, thoracoabdominal computed tomography (CT), and endoscopy detected a flat polypoid mass in the mid to lower esophagus staged at uT1, uN0 ❚Image 1A❚.
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Thoracoabdominal esophagectomy with lymphadenectomy and primary restoration of continuity by gastric pullup was performed. A 2.1 × 1.4-cm flat, polypoid mass in the esophagus ❚Image 2A❚ histologically revealed a sharply demarcated tumor arising from the basal cell layer ❚Image 3A❚. Basaloid cell clusters occasionally showed transition into cystic-adenoid formations. Immunohistochemical staining results are shown in ❚Table 1❚.
The tumor was diagnosed as BSCC of the esophagus surrounded by carcinoma in situ, according to criteria first described by Wain et al 6 in 1986, including solid growth of tumor cells in a lobular configuration, closely apposed to the surface mucosa; small, crowded cells with scant cytoplasm; dark, hyperchromatic nuclei without nucleoli; small cystic spaces containing mucin-like material; foci of coagulative necrosis in the central areas; and hyalinosis. According to the Armed Forces Institute of Pathology criteria, BSCC showed large basaloid cells with high-grade nuclei and common mitoses. 7 The cells formed solid nests, descending as strands from the overlying basal layer. The BSCC was staged at pT1b,
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❚Image 2❚ Gross pathologic findings of resected esophageal specimens. Basaloid squamous cell carcinoma as a polypoid, rough mucosal outgrowth (A) compared with a cone-shaped carcinosarcoma with sharp demarcation and protrusion into the lumen (B).
❚Image 1❚ Computed tomography scans of basaloid squamous cell carcinoma manifesting as a small polypoid mass on the lateral wall of the esophagus (A, arrow) and carcinosarcoma demonstrating a large intraluminal mass with almost complete obstruction of the esophageal lumen (B, arrow).
pN1 (1/21), cM0, G2, R0, according to the 7th edition of the TNM Classification of Malignant Tumors. 8 The postoperative clinical course was uneventful, and the patient was discharged after 1 week. He died of late surgical complications 4 months after the operation.
Case 2 (Carcinosarcoma)
A 74-year-old man had a 3-month history of dysphagia and a 10-kg weight loss. Medical history revealed an axial hiatal hernia with reflux esophagitis, arterial hypertension, and nephrolithiasis. His family history was uneventful for malignancies. Barium swallow, endosonography, and thoracoabdominal CT revealed an intraluminal mass in the mid to lower esophagus with a small stalk to mucosa, staged at uT2, uN0 ❚Image 1B❚.
Thoracoabdominal esophagectomy with lymphadenectomy and gastric pull-up was performed. Grossly, an intraluminal, polypoid, and sharply demarcated 10 × 4 × 3-cm mass showed a 1 × 0.7-cm mucosal attachment ❚Image 2B❚. The lesion exhibited a lobulated, smooth, yellow-white cut surface with small cystic lesions up to 0.5 cm. Microscopic examination revealed carcinomatous and sarcomatous components. The carcinomatous counterparts consisted of moderately differentiated clusters of basaloid squamous epithelium with solid and cystic areas, and the sarcomatous components comprised round to spindle-shaped cells with marked nuclear polymorphism and heterochromasia ❚Image 3B❚.
Immunohistochemical staining results are shown in Table 1 .
The diagnosis of carcinosarcoma of the esophagus surrounded by carcinoma in situ was established macroscopically by the presence of a bulky, polypoid mass attached to the wall by a short, thick pedicle and with its axis oriented longitudinally, in accordance with the Armed Forces Institute of Pathology criteria. 7 Characteristically, on microscopic examination the sarcomatous component included pleomorphic spindle and stellate cell sarcoma-like proliferation with bizarre mitoses and strangely shaped nuclei, and the carcinomatous component consisted of squamous cells. 7 The carcinosarcoma was staged at pT1a, pN0 (0/13), cM0, G2, R0, according to the 7th edition of the TNM Classification of Malignant Tumors. 8 uneventful, and the patient was discharged after 2 weeks. In a follow-up visit 10 months after esophagectomy, the patient reported that he was doing well.
Case 3 (Carcinosarcoma)
A 73-year-old woman had a 1-month history of retrosternal pain and dysphagia. Medical history revealed chronic reflux esophagitis, cigarette smoking (60 pack-years), chronic obstructive pulmonary disease with a 1.6 × 1.9-cm solitary pulmonary nodule of the right lower lobe, and a 2-cm right adrenal mass. Family history was uneventful for malignancies. Endoscopy and thoracoabdominal CT revealed a 2.4-cm stenosing intraluminal tumor of the esophagus. Biopsy disclosed a squamous cell carcinoma of the esophagus. Lung biopsy detected a non-small cell lung cancer with immunohistochemical expression of thyroid transcription factor-1 and focal cytokeratin (CK) 7, and negative staining for CK5/6.
Chemotherapy (6 cycles of paclitaxel/carboplatin) was applied for 4 months with minimal response of the pulmonary mass, no change in the adrenal mass, and progress of the esophageal tumor. Radiation therapy (45 Gy) for 8 weeks of the esophagus followed. Eight months later, right adrenalectomy revealed an adrenal adenoma. Thoracoabdominal esophagectomy with lymphadenectomy, gastric pull-up, and simultaneous atypical pulmonary resection were performed. A 2.3-cm polypous tumor was located in the mid to lower esophagus. Microscopic examination revealed a biphasic tumor with carcinomatous and sarcomatous components.
The tumor was diagnosed as carcinosarcoma of the esophagus and staged at ypT2, ypN0 (0/15), ycM0, G3, R0 and a synchronous 0.6-cm adenocarcinoma of the right lower lobe, staged at ypT1a, pNX, ycM0, G2, R0 according to the TNM Classification of Malignant Tumors. 8 The postoperative clinical course was uneventful, and the patient was discharged after 2 weeks.
Materials and Methods
Written informed consent was obtained from the next-ofkin for case 1 and from the patients for cases 2 and 3 for publication of the case reports and any accompanying images.
CGH from formalin-fixed and paraffin-embedded specimens of invasive BSCC, in situ carcinosarcoma, and invasive carcinosarcoma was performed as described previously. 9 Array CGH from in situ BSCC, invasive BSCC, and in situ and invasive parts of the first case of carcinosarcoma was performed essentially as described before according to the Agilent standard protocol for ULS labeling (Agilent Technologies, Waldbronn, Germany). Tumor tissue was marked in H&E-stained slides to obtain as much tumor DNA as possible. DNA was extracted from paraffin-embedded tissue blocks according to Qiagen standard procedures (Qiagen, Hilden, Germany), followed by Proteinase K treatment (1 mg/mL; Roche, Mannheim, Germany). DNA was extracted by using the QIAmp Mini Kit (Qiagen). Labeling with cyanine 3 and cyanine 5 and hybridization were performed according to Agilent (Waldbronn, Germany) protocols. The samples were hybridized against a pool of normal reference DNAs (Promega, Mannheim, Germany) on Agilent whole-genome 400 K CGH arrays. The samples were processed according to the standard Agilent CGH protocols and scanned on an Agilent Dual-Laser Scanner. Data were extracted with the Agilent Feature Extraction Software 10.5 and subsequently analyzed by using Agilent Genomic Workbench Software 5.0.
Results
On microscopic examination, BSCC and both carcinosarcomas showed a biphasic growth pattern with epithelial components of mostly basaloid differentiation with solid and cystic-glandular formation and their own stromal compartments with a loose mesenchymal pattern and sharply defined margin. The stromal component in BSCC displayed no cellular atypia, but both carcinosarcomas demonstrated increased proliferative activity and marked cellular atypia. The basaloid elements of BSCC stained positively for most epithelial markers, neuron-specific enolase (NSE), and p53, and the stromal component expressed vimentin ( Table 1) . The carcinomatous components in the carcinosarcoma stained positively for most epithelial markers and for NSE and p53. The stromal component expressed vimentin, NSE, and p53; however, NSE and p53 were expressed only weakly ( Table 1) .
CGH of the BSCC revealed gains at 1q22qter, 2pterq21, 3q, 5p, 7q11q22, 11q12q13, 12p, and 15q22qter and losses at 3p, 7q31qter, 8p12p22, 9, 11q14qter, and 21q ❚Figure 1A❚. The carcinosarcoma in case 2 showed gains at 1p36pter, 2pterq14, 7q21q22, and 11q13q14 and losses at 3p, 5q, 7q31qter, 9, 13q, and 21q ❚Figure 1B❚. The carcinosarcoma in case 3 displayed gains at 1p32p34, 2pterq13, 3q22qter, 6q25qter, 7q22q31, 8p, 10p, 11q13, and 12p and losses at 4p15qter, 13q31qter, and 18q ❚Figure 1C❚. Invasive parts of both carcinosarcomas displayed common copy number gains at 2pterq13, 7q22, and 11q13 and losses at 13q31qter. Of these alterations, gains at 2pterq13, 7q22, and 11q13 were observed in BSCC as well. In addition, array CGH was used to exactly determine the common copy number changes in BSCC and the carcinosarcoma in case 2 ❚Table 2❚. It is interesting that array CGH verified common gains at 2p25.3-2p12, 7q21.3-7q22.3, and 11q13.2-11q13.4 in invasive parts of BSCC and the carcinosarcoma in case 2 ❚Figure 2❚. In addition, copy number gains at 11q13.2-11q13.4 and 13q11-q21.1 as seen in both carcinosarcomas by using CGH could also be disclosed in array CGH, even in the in situ compartment of the carcinosarcoma in case 2. In situ BSCC displayed no copy number changes in array CGH.
Discussion
The cases examined in this study exhibited the typical pathologic and biologic features of BSCC as they were locally invasive and developed early lymphatic metastases. In contrast, carcinosarcoma manifested as a polypoid mass without metastatic spread. 10 The 1-, 2-, and 3-year survival rates in BSCC have been estimated at 60.9%, 21.7%, and 0%, respectively. 11 In carcinosarcoma, 1-, 3-, and 5-year survival rates have been estimated at 90.9%, 77.3%, and 68.2%, respectively, similar to classical SCC. 10 Thus, the different prognostic outcomes of BSCC and carcinosarcoma correlate with their different biological behavior; however, histologically, both tumors are biphasic and comprise an epithelial and a mesenchymal component. Common to both entities is the development of their own stroma, which is benign in BSCC and malignant in carcinosarcoma. A possible relation of BSCC and carcinosarcoma has been suspected in a case of esophageal carcinosarcoma with BSCC and osteosarcoma, in which the BSCC component was responsible for recurrence after resection. 12 In another case of carcinosarcoma with predominantly BSCC components, the tumor was monoclonal in origin, and distinct immunohistochemical profiles of both components suggested a possible transition from carcinomatous to sarcomatous differentiation. 13 Whether both components of carcinosarcoma are primarily monoclonal in origin or derive from 2 different precursors is still debated. 7 However, similar allelic losses and molecular analyses in 
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both components of carcinosarcoma provide evidence for a monoclonal origin from a single clone. 14, 15 Our study highlights the fact that BSCC and carcinosarcoma of the esophagus bear common chromosomal imbalances. CGH of both carcinosarcomas revealed common gains at 2pterq13 and 7q22, and 11q13 and losses at 13q31qter. Gains at 2pterq13, 7q22, and 11q13 were common to BSCC and both carcinosarcomas. Array CGH of BSCC and the carcinosarcoma in case 2 confirmed these common gains. Especially the copy number gains at 7q22.1-7q22.3 (97,323,707-106,717,666) and 11q13.2-11q13.4 (67,520,212-68,886,371; 68,912,861-70,972,158) seem to be of interest because they could be observed in all 3 examined cases.
The amplified region at 7q22 (106.624 Mb) common to BSCC, in situ carcinosarcoma, and both invasive carcinosarcomas harbors a possible microdeletion of HMG-box transcription factor 1 (HBP1) in the in situ carcinosarcoma and invasive carcinosarcomas. This protein interacts with full-length c-myc and has been described to be a transcriptional repressor and to negatively regulate the cell cycle. 16 From correlation between HBP1 underexpression and breast cancer relapse, it was suggested that HBP1 might have a role as an important tumor suppressor protein. 16 Furthermore, expression of HBP1 has been detected in SCC of the head and neck. 17 Gains at 11q13. Amplification or overexpression of CCND1 has been described to be essential in the tumorigenesis of parathyroid adenoma, breast cancer, colon cancer, lymphoma, melanoma, and prostate cancer. 18 Gains at 11q13 are described to occur in 68.6% of SCC cases, whereas the other copy number changes detected in BSCC and carcinosarcoma are not typical of SCC. 19 A study of 20 SCC cases revealed amplification of oncogenes CCND1, FGF3/FGF4, and EMS1, all located at 11q13, and SAS, ERBB2, PDGFRA, MYC, and BCL2. 20 In all 3 of our cases, positive expression of cyclin D1 could be verified immunohistochemically in the basaloid parts of the BSCC and in both components of each carcinosarcoma. In addition, array CGH detected common losses at 9p21.4 in BSCC and in situ and in invasive carcinosarcoma. Losses at 9p21 include the cyclin-dependent kinase inhibitor (CDKN2A, MIM ID *600160)/p16 (TP16), which was previously proposed to be involved in the development of tumors of lung, breast, brain, bone, skin, bladder, kidney, ovary, and lymphocytes. 21 Since Molecular cytogenetic analyses displayed many similarities but nevertheless important differences in BSCC and carcinosarcoma, with a high degree of genomic instability in contrast with the surrounding carcinoma in situ. These findings set BSCC and carcinosarcoma apart from classical SCC, and they may represent different routes of development from deletion of p16 was observed in 92% of esophageal cancer cell lines, in particular in 67% of esophagus squamous cancer cell lines, it has been suggested that loss or mutation of p16 has a critical role in the development of esophageal cancer. 22, 23 In all 3 of our cases, immunohistochemical staining for p16 was negative. 
